The Business Research Company's Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released ...

The meeting point of the stomach and esophagus, the so-called gastro-esophageal junction, is a region of the human body that ...

unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (combined positive score [CPS] of 1 or more). According to an announcement ...

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

Researchers conducted a meta-analysis of studies to explore the efficacy and safety of pembrolizumab alone and in combination with chemotherapy for the treatment of gastric and GEJ cancers.

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

as well as in conjunction with chemo as the first-line treatment of patients with gastric and gastroesophageal junction ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...